ArticleCureus2025
Comparison of Improvements in Quality of Life With Disease-Modifying Anti-rheumatic Drugs in Seropositive and Seronegative Rheumatoid Arthritis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is a chronic, progressive autoimmune disorder characterized by joint pain, stiffness, and deformities, leading to functional impairment and reduced quality of life (QoL). Disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of therapy, effectively reducing disease activity and improving health-related QoL (HRQoL).
objectiveTo compare HRQoL outcomes between seropositive and seronegative RA patients and to assess the improvement in HRQoL following initiation of conventional synthetic DMARDs (csDMARDs) in both seropositive and seronegative RA patients. METHODOLOGY: This prospective, comparative, non-randomized experimental study was conducted over 16 months and included 104 patients with RA who met the inclusion criteria - 87 seropositive and 17 seronegative. All participants received csDMARD therapy and were evaluated using the visual analogue scale (VAS) for pain, Disease Activity Score 28 (DAS28 ESR) for disease severity, and the SF-36 questionnaire for HRQoL at baseline, three months, and six months.
resultsBoth seropositive and seronegative groups showed significant improvement in HRQoL after csDMARD initiation as measured by the SF-36 index. No significant intergroup differences were observed in HRQoL outcomes. However, the seronegative group demonstrated a more pronounced reduction in pain and disease severity, as indicated by VAS and DAS28-ESR scores, compared to the seropositive group.
conclusionEarly initiation of csDMARDs in RA patients leads to significant improvement in QoL, regardless of serostatus. While both groups benefited similarly in HRQoL, seronegative patients experienced greater reductions in pain and disease activity, underscoring the efficacy of csDMARDs as an initial treatment strategy in RA management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.